#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Retatrutide and gray hair: evidence review
Community reports tie retatrutide to more gray hairs. No trial confirms this, but rapid weight loss can affect hair pigmentation in ways worth understanding.
Does Retatrutide cause muscle loss?
Phase 2 DXA data shows fat mass declining far more than lean mass, with lean loss proportional to other obesity treatments.
Combining GLP-1 drugs and tesamorelin
No trial has tested combining retatrutide, tirzepatide and tesamorelin, and here is why doing so without clinical supervision is a real risk.
Semaglutide for postpartum prediabetes
A Belgian trial is testing whether once-weekly semaglutide can stop postpartum prediabetes after gestational diabetes from becoming type 2 diabetes.
What proteomics reveals about semaglutide
A 2026 review pooled 16 proteomics studies of semaglutide in humans and animals to map which proteins and pathways the drug shifts, and how much to trust it.
What GLP-1 labels say is worth tracking
The semaglutide and tirzepatide labels name specific things to monitor on a GLP-1, and the list is not the one a weight graph suggests.
Retatrutide's overstimulated side effects
Forum users describe a wired, foggy feeling on retatrutide. Here is what the phase 2 trials recorded, and the large gap between that and anecdote.
SOUL trial: HbA1c predicts heart benefit
A July 2026 JCEM analysis of the SOUL trial found oral semaglutide's MACE benefit tracks glycaemic response more than body weight change.
Respiratory safety of weight-loss drugs
A July 2026 ATS meta-analysis of 123 studies finds no added respiratory harm from four major weight-loss drugs, but flags a gap in asthma-specific evidence.
Compounders hold on in the GLP-1 market
A June 2026 Gallup survey found nearly 1 in 5 GLP-1 users still take compounded versions, despite FDA crackdowns and pharma lawsuits.
GLP-1 and opioid overdose risk in veterans
A 2026 VHA study linked semaglutide and tirzepatide to lower overdose rates than insulin and SGLT2 inhibitors in veterans with T2D and opioid use disorder.
NVAC charter, GLP-1 telehealth: July 2026
NVAC gets a new charter on 7 July 2026, LifeMD faces GLP-1 telehealth allegations, and Medicare proposes 19% more pay for tobacco counselling.